Amanda Nizam, MD
Amanda Nizam, MD, is a GU medical oncologist at the Cleveland Clinic, specialized in treating bladder, kidney, and prostate cancer.
Articles by Amanda Nizam, MD
Dr. Koshkin highlights phase 2 data on futibatinib plus pembrolizumab for advanced urothelial carcinoma.
Drs. Tawagi, Nizam encourage earlier monitoring and intervention to mitigate EV-induced neuropathy in certain patients.
Dr. Grande discusses the importance of durvalumab for shifting the MIBC treatment landscape.
Dr. Jensen highlights the single-arm trial design and TOMBOLA's use of ctDNA.
Dr. Galsky discusses the value of HER2 status and the promising 75% ORR from the phase 2 trial.
Drs. Grande, Nizam continue their conversation on EVITA, including the personalization of treatment to predict toxicity.
Drs. Grande and Nizam discuss the development of criteria for identifying mUC patients ineligible for EV/pembro.
Drs. Gupta and Nizam discuss the findings from the patient-reported outcomes in the EV-302 trial for urothelial carcinoma.
Drs. van der Heijden and Nizam weigh the EV-302 subanalyses of the cisplatin-eligible, -ineligible populations.
Drs. Cigliola and Nizam discuss the implications of the reported SURE-01/02 study interim results.
Drs. Galsky and Nizam spotlight a phase 3 study of disitamab vedotin for la/mUC that expresses HER2.
Drs. Matthew Galsky and Amanda Nizam break down the latest data subanalysis from the CheckMate 901 trial.
Drs. Koshkin and Nizam discuss the trastuzumab deruxtecan FDA approval and the DESTINY-PanTumor02 clinical trial.
The outcomes related to sacituzumab govitecan for patients with variant histologies are highlighted.
The potential for sequencing erdafitinib and EV for patients with FGFR2/3-altered disease is considered.
The impact of squamous and other histologies on outcomes with EV are dissected.
The design of UNITE, patients sampled, and outcomes with EV after switch maintenance avelumab are explored.
Dr. Nizam provides an overview of her recent research on biomarkers of TRAEs associated with EV for aUC.
Drs. Powles and Nizam discuss her strategy of intensifying treatment upfront in oligometastatic urothelial carcinoma.
Amanda Nizam, MD, discusses her proposed trial examining EV and pembrolizumab in patients with oligometastatic UC.
630 Madison Ave.
Manalapan, NJ 07726
© 2024 Mashup Media, LLC, a Formedics Property. All Rights Reserved.